Inhibition of platelet factor 3 availability by prostacyclin

Harsfalvi, Jolan, L. Muszbek

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Preincubation of human platelet rich plasma with PGI2 in a concentration preventing collagen induced platelet aggregation abolished also platelet factor 3 availability brought about by collagen. Following PGI2 pretreatment no second wave aggregation could be elicited by ristocetin. However, primary aggregation as well as platelet factor 3 activity were only partially inhibited in this case and the inhibitory action of PGI2 was not increased by raising its concentration. Similarly, marked but not complete inhibition of platelet factor 3 availability was obtained when kaolin was used as activating agent.

Original languageEnglish
Pages (from-to)935-945
Number of pages11
JournalProstaglandins
Volume20
Issue number5
DOIs
Publication statusPublished - 1980

Fingerprint

Platelet Factor 3
Epoprostenol
Agglomeration
Availability
Platelets
Collagen
Ristocetin
Kaolin
Platelet-Rich Plasma
Platelet Aggregation
Plasmas

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Inhibition of platelet factor 3 availability by prostacyclin. / Harsfalvi; Jolan, ; Muszbek, L.

In: Prostaglandins, Vol. 20, No. 5, 1980, p. 935-945.

Research output: Contribution to journalArticle

Harsfalvi ; Jolan, ; Muszbek, L. / Inhibition of platelet factor 3 availability by prostacyclin. In: Prostaglandins. 1980 ; Vol. 20, No. 5. pp. 935-945.
@article{92ecffb87fa841fd8c57e69ccbc28c45,
title = "Inhibition of platelet factor 3 availability by prostacyclin",
abstract = "Preincubation of human platelet rich plasma with PGI2 in a concentration preventing collagen induced platelet aggregation abolished also platelet factor 3 availability brought about by collagen. Following PGI2 pretreatment no second wave aggregation could be elicited by ristocetin. However, primary aggregation as well as platelet factor 3 activity were only partially inhibited in this case and the inhibitory action of PGI2 was not increased by raising its concentration. Similarly, marked but not complete inhibition of platelet factor 3 availability was obtained when kaolin was used as activating agent.",
author = "Harsfalvi and Jolan and L. Muszbek",
year = "1980",
doi = "10.1016/0090-6980(80)90143-4",
language = "English",
volume = "20",
pages = "935--945",
journal = "Prostaglandins and Other Lipid Mediators",
issn = "0090-6980",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Inhibition of platelet factor 3 availability by prostacyclin

AU - Harsfalvi,

AU - Jolan,

AU - Muszbek, L.

PY - 1980

Y1 - 1980

N2 - Preincubation of human platelet rich plasma with PGI2 in a concentration preventing collagen induced platelet aggregation abolished also platelet factor 3 availability brought about by collagen. Following PGI2 pretreatment no second wave aggregation could be elicited by ristocetin. However, primary aggregation as well as platelet factor 3 activity were only partially inhibited in this case and the inhibitory action of PGI2 was not increased by raising its concentration. Similarly, marked but not complete inhibition of platelet factor 3 availability was obtained when kaolin was used as activating agent.

AB - Preincubation of human platelet rich plasma with PGI2 in a concentration preventing collagen induced platelet aggregation abolished also platelet factor 3 availability brought about by collagen. Following PGI2 pretreatment no second wave aggregation could be elicited by ristocetin. However, primary aggregation as well as platelet factor 3 activity were only partially inhibited in this case and the inhibitory action of PGI2 was not increased by raising its concentration. Similarly, marked but not complete inhibition of platelet factor 3 availability was obtained when kaolin was used as activating agent.

UR - http://www.scopus.com/inward/record.url?scp=0019127216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019127216&partnerID=8YFLogxK

U2 - 10.1016/0090-6980(80)90143-4

DO - 10.1016/0090-6980(80)90143-4

M3 - Article

VL - 20

SP - 935

EP - 945

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 0090-6980

IS - 5

ER -